CAS NO: | 191034-25-0 |
包装 | 价格(元) |
10 mM * 1 mL in DMSO | 电议 |
5mg | 电议 |
10mg | 电议 |
25mg | 电议 |
50mg | 电议 |
100mg | 电议 |
200mg | 电议 |
生物活性 | L-168049 is a potent, selective, orally active and non-competitiveglucagon receptorantagonist withIC50s of 3.7 nM, 63 nM, and 60 nM for human, murine, and canine glucagon receptors, respectively[1][2]. | ||||||||||||||||
IC50& Target | IC50: 3.7 nM (human glucagon receptor), 63 nM (murine glucagon receptor), and 60 nM (canine glucagon receptor)[2] | ||||||||||||||||
体外研究 (In Vitro) | L-168049 (compound 49) inhibits glucagon (100 pM) stimulated cAMP synthesis in CHO cells expressing the human glucagon receptor (hGIAR) (IC50of 41 nM). L-168049 blocks cAMP formation stimulated by glucagon in murine liver membranes[1]. | ||||||||||||||||
体内研究 (In Vivo) | In the liver of L-G6pc–/-mice, Pck1 mRNA expression is decreased by half 6 h after the administration of L-168049 (50 mg/kg body; p.o.), demonstrating the efficiency of the suppression of glucagon signaling. In agreement with the role of glucagon in the induction of extrahepatic gluconeogenesis, the administration of the L-168049 prevents the increase of the G6pc expression in both the kidneys and intestine of 6 h-fasted L-G6pc–/-mice[3]. | ||||||||||||||||
分子量 | 467.79 | ||||||||||||||||
性状 | Solid | ||||||||||||||||
Formula | C24H20BrClN2O | ||||||||||||||||
CAS 号 | 191034-25-0 | ||||||||||||||||
运输条件 | Room temperature in continental US; may vary elsewhere. | ||||||||||||||||
储存方式 |
| ||||||||||||||||
溶解性数据 | In Vitro: DMSO : ≥ 50 mg/mL(106.89 mM) *"≥" means soluble, but saturation unknown. 配制储备液
* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 |